P/E ratio for ACADIA Pharmaceuticals (ACAD)
P/E ratio as of July 2025 (TTM): 16.5
According to ACADIA Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.5109. At the end of 2024 the company had a P/E ratio of 13.5.
P/E ratio history for ACADIA Pharmaceuticals from 2004 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 13.5 | -116.38% |
| 2023 | -82.4 | 593.52% |
| 2022 | -11.9 | -46.55% |
| 2021 | -22.2 | -25.16% |
| 2020 | -29.7 | 11.08% |
| 2019 | -26.7 | 222.44% |
| 2018 | -8.29 | -35.28% |
| 2017 | -12.8 | 3.96% |
| 2016 | -12.3 | -43.65% |
| 2015 | -21.9 | -35.25% |
| 2014 | -33.8 | |
| 2012 | -12.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Vanda Pharmaceuticals VNDA | -6.27 | -137.95% | 🇺🇸 USA |
 Pfizer PFE | 17.5 | 5.93% | 🇺🇸 USA |
 Eli Lilly LLY | 65.4 | 296.12% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 18.3 | 11.02% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 17.7 | 7.37% | 🇺🇸 USA |
 Adamas Pharmaceuticals
ADMS | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.